Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

In a couple of new filings with the SEC, Hal Mintz‘s Sabby Management disclosed adding two companies to its equity portfolio: Bioline RX Ltd (NASDAQ:BLRX) and Recro Pharma Inc (NASDAQ:REPH). In RecroPharma the fund reported a 5.99% passive stake that contains 437,500 shares. In Bioline RX, Sabby revealed ownership of 1.7 million shares, equal to 5.02% of the outstanding stock.

Bioline RX Ltd (NASDAQ:BLRX) is an Israel-based company specialized in the development of therapeutics. For the last year, the company reported a net loss of $0.27 per diluted share, expanding the loss from $0.08 posted a year earlier. Among the recent highlights, the company mentioned promising phase 2 trials of its BL-8040, a drug for the treatment of AML and other hematological indications. The company also began blinded Phase 1/2 study for BL-7010, specialized fortreatment of celiac disease. The stock of the company has been declining and lost over 10% since the beginning of the year.

The largest shareholder of Bioline RX Ltd (NASDAQ:BLRX) is Samuel Isaly‘s Orbimed Advisors, which, however, cut its stake by 200,000 shares during the last quarter of 2013, and currently holds around 1.14 million shares. Richard Mashaal‘s Rima Senvest also holds a significant stake, which contains 730,310 shares, as reported in its latest 13F. James A. Silverman‘s Opaleye Management owns 713,000 shares, initiating a position during the last quarter of 2013.

Recro Pharma Inc (NASDAQ:REPH) is a newly public company, in which aside from Sabby, a stake has been reported by Kevin Kotler‘s Broadfin Capital. Broadfin in an earlier filing reported ownership of 580,000 shares, equal to 8.1% of the outstanding stock. The company began trading on March 7, and last week it closed its IPO, which involved the sale of 3.75 million shares at a price of $8.00 apiece, including over-allotment options.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.

Subscribe me to Insider Monkey's Free Daily Newsletter

This is a FREE report from Insider Monkey. Credit Card is NOT required.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.